1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Idogen AB (publ)
  6. News
  7. All News
    IDOGEN   SE0014428561

IDOGEN AB (PUBL)

(IDOGEN)
  Report
Delayed Nasdaq Stockholm  -  05/19 11:24:58 am EDT
0.4880 SEK   +6.09%
05/04Idogen publishes interim report for 1 January - 31 March 2022
AQ
05/04Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/19Idogen Receives Approval From Swedish, Norwegian Authorities For Clinical Trial Of Hemophilia Treatment
MT
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about IDOGEN AB (PUBL)
05/04Idogen publishes interim report for 1 January - 31 March 2022
AQ
05/04Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/19Idogen Receives Approval From Swedish, Norwegian Authorities For Clinical Trial Of Hemo..
MT
04/19BIOSTOCK :  Idogen's study approved in Norway and Sweden
AQ
04/19Idogen AB Announces Study Approval in Norway and Sweden
CI
04/13Idogen Appoints Chief Medical, Chief Regulatory Officers
MT
04/13Idogen strengthens the organization before the clinical development phase
AQ
04/13Idogen Strengthens the Organization Before the Clinical Development Phase
CI
04/13Idogen AB Announces Executive Appointments
CI
04/11Idogen receives approval from the Norwegian Medicines Agency, NoMA, for the start of it..
AQ
04/11Idogen AB Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of..
CI
03/31Idogen publishes annual report for 2021
AQ
03/30Idogen Appoints Two Contract Research Groups To Run Early-stage Trial Of Hemophilia Tre..
MT
03/30Idogen signs strategic collaboration agreement with contract research companies
AQ
03/30Idogen AB Signs Strategic Collaboration Agreement with KLIFO A/S and 4Pharma
CI
03/28BIOSTOCK :  Principal investigator on Idogen's clinical study with IDO 8
AQ
03/28Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phas..
CI
03/22Idogen updates in connection with the Swedish Medical Products Agency's approval of pha..
AQ
03/22Idogen AB Updates in Connection with the Swedish Medical Products Agency's Approval of ..
CI
03/14BIOSTOCK :  Leading transplant surgeon about Idogen's cell therapy
AQ
02/14Idogen announces outcome of rights issue
AQ
01/27Idogen presents the company's technology platform at a scientific congress
AQ
01/20Idogen publishes prospectus due to upcoming rights issue
AQ
01/20Bulletin from the extraordinary general meeting in Idogen AB
AQ
01/19Idogen publishes interim report for 1 January - 31 December 2021
AQ
01/19Idogen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
01/19Idogen AB Reports Earnings Results for the Full Year Ended December 31, 2021
CI
01/11Idogen adds Norway for its clinical phase 1/2a study and submits an application for app..
AQ
01/11Idogen AB Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2..
CI
2021BIOSTOCK :  Idogen submits clinical trial application
AQ
2021Idogen Submits Clinical Trial Application
CI
2021Idogen submits an application to the Swedish Medical Products Agency to initiate a clin..
AQ
2021Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A C..
CI
2021Idogen carries out a fully guaranteed rights issue of units of approximately SEK 50.4 m..
AQ
2021BIOSTOCK :  Idogen has reached milestone in clinical trial preparations
AQ
2021Idogen Completes Optimization of Cell Therapy Manufacturing Process
MT
2021CORRECTION OF DATE IN PRESS RELEASE : "Idogen has successfully completed the optimization ..
AQ
2021Idogen has successfully completed the optimization of the GMP manufacturing process for..
AQ
2021Idogen AB Completes the Optimization of the GMP Manufacturing Process for the First Cli..
CI
2021Idogen's Nomination Committee proposes re-election of Board of Directors
AQ
2021IDOGEN : Interim report Q3 2021
PU
2021IDOGEN : publishes interim report for 1 January - 30 September 2021
AQ
2021Idogen AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
CI
2021IDOGEN : announces outcome of exercise period for Series TO 4 subscription warrants
AQ
2021IDOGEN : The last day for trading in the warrants of series TO 4 in Idogen AB is today, Oc..
AQ
2021IDOGEN : Board of Directors and management of Idogen AB to exercise all of their TO 4 warr..
AQ
2021IDOGEN : Exercise period for Series TO 4 subscription warrants in Idogen begins today
AQ
2021IDOGEN : continues to optimize its production method prior to the start of the patient stu..
AQ
2021Idogen Continues to Optimize Its Production Method Prior to the Start of the Patient St..
CI
2021IDOGEN : Interim report Q2 2021
PU
2021IDOGEN : publishes interim report for 1 January - 30 June 2021
AQ
2021Idogen AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021IDOGEN : European patent granted relevant to Idogen's cell therapy for hemophilia A
AQ
2021BIOSTOCK :  Idogen's CEO on World Transplant Day and IDO T against organ rejection
AQ
2021IDOGEN : Bulletin from the annual general meeting in Idogen AB on May 11, 2021
AQ
2021Idogen AB Appoints Lennart Svensson as New Board Member
CI
2021IDOGEN : publishes interim report for 1 January - 31 March 2021
AQ
2021Idogen AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
2021IDOGEN : BioStock interview with Åsa Schiött, Chief Scientific Officer at Idogen
AQ
2021IDOGEN : BioStock interview with Rolf Ljung, scientific advisor to Idogen
AQ
2021IDOGEN : The European Patent Office intends to grant Idogen's patent application relevant ..
PU
2021IDOGEN : The European Patent Office intends to grant Idogen's patent application relevant ..
AQ
2021Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent Ap..
CI
2021IDOGEN : publishes Year-end report for 2020
AQ
2021Idogen AB Announces Executive Changes
CI
2021Idogen AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
CI
2020IDOGEN : Interim report January 1– September 30, 2020
PU
2020IDOGEN AB : Interim report January 1- September 30, 2020
AQ
2020Idogen AB Reports Earnings Results for the Third Quarter Ended September 30, 2020
CI
2020IDOGEN : provides update on timelines for the development of the tolerogenic cell therapy ..
PU
2020IDOGEN : provides update on timelines for the development of the tolerogenic cell therapy ..
AQ
2020Idogen Provides Update on Timelines for the Development of the Tolerogenic Cell Therapy..
CI
2020IDOGEN AB : Interim report
AQ
2020IDOGEN PUBL : has been approved for listing on Nasdaq First North Growth Market
PU
2020IDOGEN PUBL : cell therapy product successfully produced by GMP-certified manufacturing pa..
AQ
1  2Next
Upcoming event on IDOGEN AB (PUBL)